Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

Now Viewing

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

Augmented Hyper-CVAD (AHCVAD) in Young Adult ALL: Key Insights

Study Overview

• Research focused on adults younger than 50 years with acute lymphoblastic leukemia (ALL).
• Investigated a pediatric-inspired treatment regimen (AHCVAD)

Key Findings

• High rates of MRD negativity
• Favorable 3-year overall survival
• Treatment effectiveness demonstrated regardless of allogeneic stem cell transplant status

Clinical Implications

• Challenges traditional age-based treatment paradigms
• Suggests potential benefits of adapting pediatric treatment strategies for young adult patients with ALL
• Demonstrates promising outcomes with an aggressive, pediatric-inspired approach

Potential Practice Changes

• Consider evaluating pediatric-inspired regimens for young adult patients with ALL.
• Emphasize MRD assessment as a critical treatment response marker.
• Individualize treatment strategies based on patient characteristics beyond age.

Limitations and Considerations

• Single-center experience
• Focused on patients younger than 50 years

Further multicenter studies needed to validate findings